Bulletin
Investor Alert

Market Pulse Archives

Oct. 23, 2015, 12:08 p.m. EDT

At a $749 a pop discount, Martin Shkreli's AIDS drug has a new rival

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Tonya Garcia

Imprimis Pharmaceuticals said it is offering customizable compounded alternatives to Turing Pharmaceuticals' high-priced Daraprim for as low as $99 for a 100-count bottle. Turing bought the U.S. rights to Daraprim in August and promptly increased the price of the drug from $13.50 per tablet to $750 per tablet, leading to backlash and headlines last month. Both Daraprim and Imprimis' alternative are prescribed for infections afflicting patients with compromised immune systems, including patients with HIV/AIDS, pregnant women and children. The price hike raised questions about how prescription drugs can cost so much. Imprimis is also creating a new program, Imprimis Cares, that aims to provide these compounded formulations to combat high-priced generic drugs. Imprimis Pharmaceuticals is down 20.4% for the year so far. The Nasdaq is down 1.9% for the same period.

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.